Skip to content
RXSTRxSight, Inc.

Earnings

When RxSight, Inc. reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 24, after the close

Wed, Feb 24, 2027in 98 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 11

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$32.61M
Revenue, change from a year earlier: Q3 2026 −19.1%, Q2 2026 −19.0%, Q1 2026 −18.5%, Q4 2025 −18.9%
Net income
-$9.15M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$24.55M−19.1% vs Q3 2025

Latest results

  1. Q3 2026Nov 3, 2026, after the closeThe release+8.3%by the close of Nov 4
    Revenue
    $24.55M
    −19.1%
    Net income
    -$16.22M
    N/M
    EPS
    -$0.39
    N/M
    On November 3, 2026, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three months ended September 30, 2026.
  2. Q2 2026Aug 5, 2026, after the closeThe release3.3%by the close of Aug 6
    Revenue
    $27.24M
    −19.0%
    Net income
    -$12.10M
    N/M
    EPS
    -$0.29
    N/M
  3. Q1 2026May 6, 2026, after the closeThe release14.7%by the close of May 7
    Revenue
    $30.89M
    −18.5%
    Net income
    -$15.88M
    N/M
    EPS
    -$0.38
    N/M
  4. Q4 2025Feb 25, 2026, after the closeThe release9.8%by the close of Feb 26
    Revenue
    $32.61M
    −18.9%
    Net income
    -$9.15M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 3, 2026 · after-hoursNov 3, 202634 d10-Q$24.55M−19.1%-$0.39+8.3%
Q2 2026Jun 30, 2026Aug 5, 2026 · after-hoursAug 5, 202636 d10-Q$27.24M−19.0%-$0.293.3%
Q1 2026Mar 31, 2026May 6, 2026 · after-hoursMay 6, 202636 d10-Q$30.89M−18.5%-$0.3814.7%
FY 2025
Q4 2025derivedDec 31, 2025Feb 25, 2026 · after-hoursFeb 25, 202656 d10-K$32.61M−18.9%—9.8%
Q3 2025Sep 30, 2025Nov 5, 2025 · after-hoursNov 5, 202536 d10-Q$30.34M−14.1%-$0.24+3.6%
Q2 2025Jun 30, 2025Aug 7, 2025 · after-hoursAug 7, 202538 d10-Q$33.64M−3.6%-$0.297.0%
Q1 2025Mar 31, 2025May 7, 2025 · after-hoursMay 7, 202537 d10-Q$37.90M+28.4%-$0.2011.2%
FY 2024
Q4 2024derivedDec 31, 2024Feb 25, 2025 · after-hoursFeb 25, 202556 d10-K$40.21M+40.7%—0.9%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q$35.31M+59.1%-$0.166.0%
Q2 2024Jun 30, 2024Aug 5, 2024 · after-hoursAug 5, 202436 d10-Q$34.89M+67.6%-$0.16—
Q1 2024Mar 31, 2024May 6, 2024 · after-hoursMay 6, 202436 d10-Q$29.51M+68.7%-$0.25—
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 3, 2026445381
10-QAug 5, 2026335153
10-QMay 6, 2026208921
10-KFeb 25, 2026071775
10-QNov 5, 2025266986
10-QAug 7, 2025105070
10-QMay 7, 2025065683
10-KFeb 25, 2025026681
10-QNov 7, 2024123368
10-QAug 5, 2024090770

Provenance

ProvenanceData status and checks

RxSight, Inc. · CIK 1111485 · Engraved from SEC EDGAR